Plasminogen activator inhibitor type 2 in breast cancer

British Journal of Cancer

Volumn 76, Issue 5, 1997, Pages 622-627

  Duggan, C ^a   Kennedy, S ^b   Kramer, M D ^c   Barnes, C ^b   Elvin, P ^d   McDermott, E ^a   O'Higgins, N ^a   Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^c Inst Immunol und Serologie D   (Germany)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Enzyme linked immunosorbent assay; Immunochemistry; Northern blotting; Plasminogen activator inhibitor 1; Plasminogen inhibitor activator 2; Tissue plasminogen activator; Urokinase plasminogen activator

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL;

EID: 0030873151     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.435     Document Type: Article

References (23)

1. Andreasen P, Georg B, Lund LR, Riccio R and Stacey S (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19
2. Åstedt B, Lecander I and Ny T ( 1987) Placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis I: 203-208
3. Åstedt B, Billström A, Lecander I (1995) Urokinase-producing tumour growth in SCID mice inhibited by recombinant PAI-2. Fibrinol 9: 175-177
4. Baker MS, Bleakley P, Woodrow GC, Doe WF (1990) Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Rex 50: 4676-1684
5. Bianchi E, Cohen RL, Dai A, Thor AT, Schuman MA, Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603
6. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
7. Cajot JF, Bamat J, Bergonzelli GE, Kruithof E. Medcalf RL, Testuz J. Gordat B (1990) Plasminogen-activator inhibitor type-1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Nail Acad Sei USA 87: 6939-6943
8. Chomczynski P, Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biocheni 162: 156-159
9. Duffy MJ (1993) Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7: 295-302
10. Duffy MJ (1996) Proteases as prognostic markers in cancer. J Clin Cancer Res 2: 613-618
11. Duffy MJ, O'Siorain L, Waldron B, Smith C (1986) Estradiol receptor in human breast carcinomas assayed by use of monoclonal antibodies. Clin Chem 32: 1972-1974
12. Duffy MJ, O'Grady P Devaney D. O'Siorain L. Fennelly JJ. Lijnen HR (1988) Tissue-type plasminogen activator: a new prognostic marker in breast cancer. Cancer Res 48. 1348-1349
13. Duggan C, Maguire T, McDermott E. O'Higgins N, Fennelly JJ. Duffy MJ ( 1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
14. Foekens JA, Schmitt M, van Pulten WLJ, Peters HA, Kramer M, Jånicke F, Klijn JGM ( 1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
15. Foekens JA, Buessekler F, Peters HA, Krainick U, van Putten W, Look MP, Khjn JGM, Kramer M ( 1995) Plasminogen activator inhibitor 2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427
16. Foucre D, Bouchet C, Hacene K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J (1991) Relationship between Cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64. 926-932
17. Grøndahl-Hansen J, Christensen IJ. Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M ( 1993) High levels of urokinase-type plasminogen activator and its inhibitor PA1-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
18. Jänicke F. Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 24: 195-208
19. Mueller B, Yu YB, Laug W (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in seid/seid mice. P roc Natl Acad Sei USA 92: 205-209
20. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K (1991) The plasminogen activator system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the human stroma. Cancer Res 51: 4067-4071
21. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen P (1992) Type I plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214
22. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwann HC (1995) Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor associated angiogenesis. and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96: 2593-2600
23. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A and Baba S (1992) Plasminogen activator system in human breast cancer. Int J Cancer 50: 345-348